Open Access Open Access  Restricted Access Subscription or Fee Access

Analysis of Virechana Karma with Trivritta Avaleha: A Retrospective Study

Satyajit Pandurang Kulkarni, Shivananda S. Tonde, Yashwant R. Patil

Abstract


The Virechana (therapeutic purgation) is one of the popular Panchakarma procedures which has been performed to maintain the health and treat various ailments such as constipation, skin diseases, menstrual disorders etc. The ancient classical texts have described the procedure of Virechana Karma in detail, but, it becomes practically difficult to perform the Virechana Karma as the drugs mentioned for Virechana Karma in the classical texts are either not available in the market or the dose mentioned in the texts is not in present terminology. Trivritta (Operculina turpethum) is such a drug which is used in the form of Trivritta Avaleha available in the market. The Trivritta is mentioned as the best drug for Virechana (therapeutic purgation). But analysis of Virechana Karma with Trivritta Avaleha is not studied yet. Therefore, it becomes difficult to decide the dose of Trivitta Avaleha for Virechana Karma. Chaganti and Prasad carried out analysis of Danti Avaleha, which is another drug for Virechana, however such kind of study of Trivritta Avaleha has been not carried out yet. Therefore, the present study was carried out. In this case series, total 13 healthy individuals were observed from the initiation of the course to end with special reference to the dose of Trivirtt Avaleha and outcome of Virechana. It was observed that out of 13 individuals, eight  had Pravara (excellent) Shuddhi, four had Madhyama (medium) Shuddhi and one individual having Avara (minimum) Shuddhi. In the end, it was concluded that 25 g is the minimum effective dose of Trivritt Avaleha for Virechana in Madhyama Koshtha and it is 30 g in case of Krur Koshtha.


Keywords


Virechana Karma, Trivritta Avaleha, Virechak Dravya dose, Koshtha, Uttam Shuddhi

Full Text:

PDF

References


Pandit KS, Chaturvedi GN, et al. Charaka Samhita of Agnivesha Siddhisthana 2/13. Varanasi, India: Chaukhambha Bharati Academy; 2001. 981p.

Pandit KS, Chaturvedi GN, et al. Charaka Samhita of Agnivesha Siddhisthana 2/13. Varanasi, India: Chaukhambha Bharati Academy; 2001. 981p.

Dave A, Shingala T, Kumari J, Mehta C, Shukla V. A comparative clinical study of Nyagrodhadi Ghanavati and Virechana Karma in the management of Madhumeha. Ayu (An Int Q J Res Ayurveda). 2010; 31(3): 300–304p.

Mangal G, Sharma R, Mangal G. Clinical efficacy of Shodhana Karma and Shamana Karma in Mandala Kushtha (Psoriasis). Ayu (An Int Q J Res Ayurveda). 2012; 33(2): 224–229p.

Chaganti S, Prasad BS. Analysis of Virechana karma with Danti avaleha: A retrospective study. J Ayurveda Integr Med. 2015; 6(4): 300–304p.

Chaturvedi A, Rao PN, Kumar MA, Ravishankar B, Rao N, Ravi M. Effect and Mechanism of Virechana Karma (Therapeutic Purgation) Over Fructose-Induced Metabolic Syndrome: An Experimental Study. J Evidence-Based Complement Altern Med. 2016; 21(3): 194–201p.

Kolhe R, Acharya RN. Trivrut and Its Important in the Classical Text of Ayurveda : A Comprehensive Review. 2014; 1(2): 33–53p.

Rais A, Bhatted S. Clinical study to evaluate the effect of Virechanakarma on serum electrolytes. Ayu (An Int Q J Res Ayurveda). 2013; 34(4): 379–382p.

Shastri PK, Chaturvedi GN, et al. Charaka Samhita of Agnivesha Siddhisthana 2/13. Varanasi, India: Chaukhambha Bharati Academy; 2001. 981p.

Sharma M, Parashar B, Kalpana, Devi N. Formulation and Evaluation of Hingwashtak Churna for Digestive Property: A Research. World Journal of Pharmaceutical Research. 2019; 8(7): 2332–2344p.

Vagbhata. Ashtang Hridaya. Tripathi DB, Editor. Varanasi: Chaukhambha; 2019. 1379p.

Chaganti S, Prasad BS. Analysis of Virechana karma with Danti avaleha: A retrospective study. J Ayurveda Integr Med. 2015; 6(4): 300–304p.

Chaturvedi A, Rao PN, Kumar MA, Ravishankar B, Rao N, Ravi M. Effect and Mechanism of Virechana Karma (Therapeutic Purgation) Over Fructose-Induced Metabolic Syndrome: An Experimental Study. J Evidence-Based Complement Altern Med. 2016; 21(3): 194–201p.


Refbacks

  • There are currently no refbacks.